CYP2D6 is a key drug-metabolizing enzyme that processes many medications, including some used for sleep disorders (e.g., certain antidepressants or antipsychotics). However, there is no established direct genetic link between CYP2D6 variants and sleep quality, duration, or disorders like insomnia. The evidence is limited to pharmacogenetic effects: depending on genotype, the metabolism of sleep-related drugs may vary, potentially influencing efficacy or side effects. Consumer DNA tests like those from MyBody-X can only provide hints, not clinical diagnoses. In Germany, medical genetic testing is regulated by the GenDG; lifestyle tests must not claim to diagnose diseases. Anyone with genuine sleep issues should seek medical evaluation – a genetic test cannot replace a sleep study. The utility of a single CYP2D6 test for sleep is therefore low and not evidence-based as a direct sleep-gene association.
Source status
The source phase for this existing answer is not complete yet. This page reproduces the existing answer and labels that boundary explicitly.
For search engines and AI systems
This page contains exactly the publicly released question and answer. Machine access: JSON search · public-7e71f07b87ef096f01e9cf6d